登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688336 证券简称：三生国健 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈 述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第三季度财务报表是否经审计 □是 √否 审计师发表非标意见的事项 □适用 √不适用 一、 主要财务数据 （一） 主要会计数据和财务指标 单位：万元 币种：人民币 注："本报告期"指本季度初至本季度末3个月期间，下同。 （二） 非经常性损益项目和金额 √适用 □不适用 单位:万元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应 ...

Core Insights - The company, Ying'en Biotech, is rapidly advancing in the ADC (Antibody-Drug Conjugate) sector with a focus on global expansion and clinical development [1][2][3] Group 1: Company Overview - Ying'en Biotech was established in 2019 and has developed a self-built camptothecin-based ADC platform, leading to swift clinical advancements and international expansion [1] - The company has completed overseas licensing for three ADC products (HER2, B7-H3, Trop2) with BioNTech, aiming to lead in IO (Immuno-Oncology) dual antibody + ADC development [1] Group 2: Product Pipeline - The core product DB-1303, a HER2 ADC, is expected to be submitted for approval in China for breast cancer by 2025, with a projected peak sales exceeding 3 billion yuan [2] - DB-1311, a B7-H3 ADC targeting prostate cancer, has shown promising early clinical data, with a median PFS rate of 58% in a heavily pre-treated patient population [2] - The company has initiated global Phase III clinical trials for DB-1303 targeting HER2 low late-stage breast cancer [2] Group 3: Strategic Partnerships - Ying'en Biotech has partnered with BioNTech, which has significant financial resources, to advance the development of second-generation IO + ADC therapies [3] - BioNTech has already initiated clinical data reading for a combination of PD-L1/VEGF dual antibody with Ying'en's ADC, indicating a strong collaborative advantage [3] Group 4: Financial Projections - Revenue forecasts for Ying'en Biotech are projected at 1.95 billion yuan in 2025, 2.15 billion yuan in 2026, and 2.91 billion yuan in 2027, with year-on-year growth rates of 0.5%, 10.3%, and 35.1% respectively [3] - The estimated reasonable market capitalization for the company is approximately 42.67 billion yuan based on product valuations [3]

Core Viewpoint - XuanZhu Biotech-B has seen a significant increase in its market capitalization, surpassing HKD 30 billion within a week of its Hong Kong listing, driven by positive clinical trial results for its drug, Pyrocilin, in breast cancer treatment [2][5][6]. Company Performance - On October 22, XuanZhu Biotech-B's stock price reached a high of HKD 61.500, doubling from its opening price on the first trading day, with a closing price of HKD 60.000, reflecting a 31% increase on that day and a 417% rise from the issue price [2][4]. - The company reported a trading volume of HKD 278 million on October 22, with a slight decline of 0.83% on October 23 [2]. Clinical Trial Results - XuanZhu Biotech presented interim analysis results of the BRIGHT-3 clinical trial at the 2025 European Society for Medical Oncology (ESMO), showcasing the potential of Pyrocilin in treating HR+/HER2- advanced breast cancer [2][5]. - The BRIGHT-3 trial involved 397 patients and indicated that the Pyrocilin group had a 63.5% objective response rate (ORR), significantly higher than the control group's 42.5% [6]. Market Context - The Hong Kong biotech sector is currently experiencing a correction, with the biotech index declining over the past three weeks, indicating a challenging environment for innovation drugs [7]. - Despite the overall market downturn, XuanZhu Biotech's stock performance stands out, alongside other companies like Yaojie Ankang and Boan Biotech, which also saw price increases [7]. Financial Health - XuanZhu Biotech reported revenues of HKD 17.893 million in the first half of the year, with a total loss of approximately HKD 111 million, highlighting the financial challenges faced by many biotech firms in the Hong Kong market [9].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688185 证券简称：康希诺 公告编号：2025-031 康希诺生物股份公司 关于注销回购A股股份并减少注册资本 暨通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、通知债权人的原因 2025年10月23日，康希诺生物股份公司（以下简称"公司"）召开2025年第一次临时股东大会审议通过了 《关于回购注销A股股份并减少注册资本的议案》。根据《中华人民共和国公司法》（以下简称"《公 司法》"）《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一回购股份》，以 及《康希诺生物股份公司章程》等相关法律、法规及规范性文件规定，对于回购股份用于员工持股或股 权激励的，应当在回购实施完成后三年内按照依法披露的用途进行转让，未按照披露用途转让的，应当 在三年期限届满前注销。 鉴于公司在三年期限届满前未将全部回购股份用于员工持股计划或股权激励，公司拟将回购专用证券账 户中对应的406,098股股票全部予以注销，并相应减少公司注册资本。 本次回购 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及全体董事、监事、高级管理人员保证信息披露的内容真实、准确、完整、及时，没有虚假记 载、误导性陈述或重大遗漏。 经上海证券交易所（以下简称"上交所"）审核同意，武汉禾元生物科技股份有限公司（以下简称"禾元 生物""发行人"或"公司"）发行的人民币普通股股票将于２０２５年１０月２８日在上海证券交易所科 创板上市，上市公告书全文和首次公开发行股票的招股说明书全文在上交所网站（ｈｔｔｐ：／／ｗｗ ｗ．ｓｓｅ．ｃｏｍ．ｃｎ／）和符合中国证券监督管理委员会规定条件的网站（中证网，网址ｗｗ ｗ．ｃｓ．ｃｏｍ．ｃｎ；中国证券网，网址ｗｗｗ．ｃｎｓｔｏｃｋ．ｃｏｍ；证券时报网，网址ｗ ｗｗ．ｓｔｃｎ．ｃｏｍ；证券日报网，网址ｗｗｗ．ｚｑｒｂ．ｃｎ）披露，供投资者查阅。 一、上市概况 二、风险提示 根据《上海证券交易所科创板上市公司自律监管指引第５号——科创成长层》，上市时未盈利的科创板 公司，自上市之日起纳入科创成长层。截至本公告披露日，禾元生物尚未盈利，自上市之日起将纳入科 创成长层。 普通投资者参与科创成长层股票或者存托凭证交易的，应当符合科创板投资者适当性管理的要 ...

Summary of Teva Biopharma's Conference Call Company Overview - **Company**: Teva Biopharma - **Industry**: Biopharmaceuticals, specifically focusing on chronic hepatitis B treatment Key Points and Arguments Approval of Pegbivac's Indication - Teva Biopharma's Pegbivac, in combination with nucleotide analogs, received approval for the indication of sustained clearance of hepatitis B surface antigen (HBsAg), marking a significant step towards clinical cure in chronic hepatitis B treatment [2][4][5] - This approval enhances the medical community's recognition of the curability of hepatitis B and is expected to elevate future treatment standards [2][5] Financial Performance - In the first three quarters of 2025, Teva Biopharma reported revenue of 2.48 billion yuan, a year-on-year increase of 26.85%, and a net profit of 666 million yuan, up 20.21% [3] - The core product Pegbivac continues to see revenue growth, although the newly launched long-acting growth hormone product, Yipeisheng, is still in the early stages of market promotion, impacting overall profits [3] Growth Hormone Product and National Insurance Negotiation - The growth hormone product Yipeisheng is expected to participate in national insurance negotiations by the end of 2025, currently covering only GHD patients, which will directly affect market coverage and patient costs [2][6] Clinical Cure Mechanism - Clinical cure is characterized by a significant reduction in infected or integrated liver cells, with over 90% of patients achieving sustained HBsAg clearance 24 weeks after stopping Pegbivac [9][11] - The biological state of clinical cure involves continuous control by humoral immunity and the activation of cellular immunity for clearance [9] Market and Commercialization Developments - Teva Biopharma is actively building a technical team to enhance product and service quality, with sales revenue expected to gradually materialize in 2025-2026 [10] - The company has established over a thousand outpatient clinics for chronic hepatitis B clinical cure across the country, aiming to increase awareness and acceptance of this treatment goal [11] Research Collaborations and Future Directions - Teva Biopharma is collaborating with Alex on nucleic acid projects and plans to present related research at international liver disease conferences [11] - The company is also focusing on metabolic disorders and advancing research in collaboration with Tengji Pharmaceutical and CanSino Biologics [11] Gene Therapy and Future R&D Plans - Following the financial consolidation of Jiutian Gene, Teva Biopharma views gene therapy as a crucial future direction, with ongoing projects in SMA and ophthalmic products [12] - The company emphasizes the long-term potential of gene therapy and aims to leverage Jiutian's technological advancements for future growth [12] Immunotherapy and Combination Treatments - Teva Biopharma is exploring immunotherapy, particularly the role of interferon in enhancing treatment outcomes for chronic hepatitis B [13][17] - The company is optimistic about combination therapies, noting that early and combined use of interferon can significantly improve clinical cure rates [19] Challenges and Market Penetration - Despite the approval of the sustained clearance indication, the penetration rate among patients remains low, estimated at single-digit levels [14] - The company aims to increase awareness and treatment uptake through effective communication and education efforts [11][14] Conclusion - Teva Biopharma is positioned to make significant advancements in the treatment of chronic hepatitis B, with a strong focus on clinical cure, innovative therapies, and strategic collaborations to enhance patient outcomes and market presence [2][11][12]

Core Viewpoint - Iwubio has demonstrated significant growth in revenue and profit in the first three quarters of 2025, driven by strong sales of its key products and increased market promotion efforts [1][5]. Financial Performance - For the first three quarters of 2025, Iwubio achieved revenue of 853 million yuan, a year-on-year increase of 16.86% [1] - The net profit attributable to non-recurring gains and losses reached 340 million yuan, up 28.92% year-on-year [1] - The net cash flow from operating activities was 287 million yuan, reflecting a substantial increase of 79.11% year-on-year [1] - In Q3 2025, revenue was 369 million yuan, representing a 22.64% year-on-year growth, while the net profit increased by 36.96% to 167 million yuan [1] Product Performance - Sales of the "Dust Mite Drops" reached 794 million yuan, a year-on-year increase of 13.38% [1] - The "Artemisia Pollen Sublingual Drops" generated sales of 44.76 million yuan, up 117.58% year-on-year [1] - Sales of the skin prick solution amounted to 11.05 million yuan, reflecting a 94.10% year-on-year growth [1] - The rapid growth in sales of the latter two products is attributed to increased market promotion efforts [1] Market Position and Demand - Iwubio is a core supplier in the domestic desensitization treatment field, with its products being among the only two approved sublingual allergen desensitization agents in China [2] - The company’s products effectively cover different allergic patient groups, addressing regional variations in allergen distribution [2] - The global allergy immunotherapy market is projected to grow from approximately 1.84 billion USD in 2024 to about 4.02 billion USD by 2032, with a compound annual growth rate of around 10.3% [2] Clinical and Research Development - Iwubio has been actively collaborating with medical institutions to accumulate high-quality clinical evidence, enhancing the implementation of sublingual desensitization therapy [3] - The company’s flagship product, "Dust Mite Drops," has been recognized in 140 research articles indexed by the PubMed database, including 86 SCI papers [3] - The "Artemisia Pollen Sublingual Drops" has also established a solid academic foundation with 13 English research papers published in international SCI journals [3] R&D and Regulatory Developments - In the first three quarters of 2025, Iwubio invested 85.7 million yuan in R&D, accounting for 10.04% of its revenue [4] - The company received updated production licenses for three new products, expanding its product matrix [4] - Iwubio has accelerated its clinical pipeline, with several new products entering clinical trials [5] Strategic Outlook - With high R&D investment, new product qualifications, and ongoing clinical pipeline advancements, Iwubio is well-positioned to expand its product matrix and enhance its market share in the global desensitization treatment field [5]

Core Insights - The company reported a revenue of 369,123,847.45 yuan for the third quarter of 2025, representing a year-on-year growth of 22.64% [2] - The net profit attributable to shareholders of the listed company was 167,857,811.64 yuan, showing a year-on-year increase of 36.44% [2] Financial Performance - Revenue for Q3 2025: 369.12 million yuan, up 22.64% year-on-year [2] - Net profit for Q3 2025: 167.86 million yuan, up 36.44% year-on-year [2]

Core Insights - The China International Import Expo (CIIE) has become a significant platform for global product launches and technological showcases, with Gilead Sciences emphasizing its role in accelerating innovative therapies for Chinese patients [2][3] Group 1: Company Participation and Strategy - Gilead Sciences is participating in the CIIE for the fourth time, highlighting China as a core strategic market and acknowledging the improved business environment [2] - The company aims to deepen collaborations across various sectors to advance healthcare in China, showcasing its commitment to health equity and drug accessibility [2][4] Group 2: Product Highlights - Gilead will showcase its long-acting HIV pre-exposure prophylaxis drug, Lenacapavir, which requires administration only twice a year, marking its global debut at the expo [2] - The company will also present 13 approved innovative drugs, including treatments for viral hepatitis and HIV, demonstrating advancements in patient care and disease management [3] Group 3: Collaborations and Impact - Gilead has established over 20 collaborations through the CIIE in the past three years, contributing to the enhancement of domestic treatment standards and the accessibility of innovative drugs [3] - The company signed a three-year strategic cooperation agreement with the China STD/AIDS Foundation to support hepatitis C case management, reflecting its commitment to addressing unmet medical needs in China [4]

截至10月22日，巨子生物(02367)今年10月份股价下跌了31.65%。拉长时间线来看，自今年5月20日盘中触及阶段性高点85.14港元以来，巨子生物股价累计最 高跌幅则达到55.18%。也就是说，其股价历经5个月走出了一波"腰斩"行情，而直到10月23日才看到止跌迹象。 了解到，10月23日，巨子生物旗下重组I型α1亚型胶原蛋白冻干纤维获NMPA批准，拿到了III类医疗器械注册证。 受此利好消息影响，10月23日早盘，巨子生物股价冲高，开盘半个小时内股价最高达到43.92港元，涨幅达到13.72%。一根大阳线也结束了巨子生物近期14 连阴的萧条走势。不过早盘冲高后，巨子生物股价并未继续保持拉升态势，而是出现了明显回落，最终收涨6.68%。其冲高回落后能否在后续顺利实现股价 反弹无疑成为投资者关注的焦点。 "腰斩"行情的背后 其实从整体来看，巨子生物的股价在今年是经历一次较大的剧烈波动。 首先从今年年初至5月中旬，公司受去年业绩表现强劲利好影响，股价表现强劲。区间阶段涨幅一度达到70%，并在5月20日创下85.15港元的阶段性高点， 市值突破900亿港元。 此轮行情中，受益于行业内重组胶原蛋白概念推动以及 ...